Arnaud Panes1, Hélène Verdoux1,2, Annie Fourrier-Réglat1,3, Driss Berdaï3, Antoine Pariente1,3, Marie Tournier1,2. 1. Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, Bordeaux, France. 2. Hospital Charles Perrens, Bordeaux, France. 3. Public Health Department, Medical Pharmacology Unit, University hospital of Bordeaux, Bordeaux, France.
Abstract
AIMS: Use and misuse of benzodiazepine might be very prevalent in patients with acute psychiatric symptoms, whereas they might be associated with specific adverse events in this population. The study investigated their prevalence in these patients. Secondary objectives were to identify risk factors for misuse of benzodiazepines, and its impact. METHODS: A cohort study was based on the hospital's electronic patient records and conducted in patients aged 18 years and over and admitted to a psychiatric hospital. They were followed up for 84 days or until the end of hospitalisation. Four variables of misuse were built: excessive duration of treatment, type of product, excessive dosage and concomitant benzodiazepines. Backward stepwise multivariate logistic regression analysis was used to assess risk factors for each misuse criterion, on the 1 hand, and impact of benzodiazepine misuse, on the other. RESULTS: In total, 511 psychiatric inpatients were included with 89.0% of them exposed to benzodiazepine. Discharge prescription included no benzodiazepine or a dosage lower than the maximum dosage prescribed during hospitalisation for 78.2% of patients exposed to benzodiazepine during their stay. Of benzodiazepine treatments, 31.4% were associated with at least 1 misuse criterion. Excessive dosage was associated with age ≥65 years (OR 11.57; 95% confidence interval 4.92-27.17), substance/alcohol use disorders (3.35; 95% confidence interval 1.70-6.62) and parenthood (0.49; 0.25-0.97). Some criteria of benzodiazepine misuse were associated with a higher frequency of adverse events occurring after treatment initiation. CONCLUSIONS: Misuse of benzodiazepines is very common in inpatients with psychiatric disorders. These findings should alert clinicians to comply with clinical recommendations.
AIMS: Use and misuse of benzodiazepine might be very prevalent in patients with acute psychiatric symptoms, whereas they might be associated with specific adverse events in this population. The study investigated their prevalence in these patients. Secondary objectives were to identify risk factors for misuse of benzodiazepines, and its impact. METHODS: A cohort study was based on the hospital's electronic patient records and conducted in patients aged 18 years and over and admitted to a psychiatric hospital. They were followed up for 84 days or until the end of hospitalisation. Four variables of misuse were built: excessive duration of treatment, type of product, excessive dosage and concomitant benzodiazepines. Backward stepwise multivariate logistic regression analysis was used to assess risk factors for each misuse criterion, on the 1 hand, and impact of benzodiazepine misuse, on the other. RESULTS: In total, 511 psychiatric inpatients were included with 89.0% of them exposed to benzodiazepine. Discharge prescription included no benzodiazepine or a dosage lower than the maximum dosage prescribed during hospitalisation for 78.2% of patients exposed to benzodiazepine during their stay. Of benzodiazepine treatments, 31.4% were associated with at least 1 misuse criterion. Excessive dosage was associated with age ≥65 years (OR 11.57; 95% confidence interval 4.92-27.17), substance/alcohol use disorders (3.35; 95% confidence interval 1.70-6.62) and parenthood (0.49; 0.25-0.97). Some criteria of benzodiazepine misuse were associated with a higher frequency of adverse events occurring after treatment initiation. CONCLUSIONS: Misuse of benzodiazepines is very common in inpatients with psychiatric disorders. These findings should alert clinicians to comply with clinical recommendations.
Authors: Jari Tiihonen; Ellenor Mittendorfer-Rutz; Minna Torniainen; Kristina Alexanderson; Antti Tanskanen Journal: Am J Psychiatry Date: 2015-12-07 Impact factor: 18.112
Authors: David A Brent; Laurence L Greenhill; Scott Compton; Graham Emslie; Karen Wells; John T Walkup; Benedetto Vitiello; Oscar Bukstein; Barbara Stanley; Kelly Posner; Betsy D Kennard; Mary F Cwik; Ann Wagner; Barbara Coffey; John S March; Mark Riddle; Tina Goldstein; John Curry; Shannon Barnett; Lisa Capasso; Jamie Zelazny; Jennifer Hughes; Sa Shen; S Sonia Gugga; J Blake Turner Journal: J Am Acad Child Adolesc Psychiatry Date: 2009-10 Impact factor: 8.829
Authors: G Fond; L Boyer; M Favez; L Brunel; B Aouizerate; F Berna; D Capdevielle; I Chereau; J M Dorey; C Dubertret; C Faget; F Gabayet; H Laouamri; C Lancon; Y Le Strat; D Misdrahi; R Rey; C Passerieux; A Schandrin; F Schurhoff; A M Tronche; M Urbach; P Vidalhet; P M Llorca; A Pelissolo Journal: Psychopharmacology (Berl) Date: 2015-12-03 Impact factor: 4.530
Authors: Guillermo Santos-Sánchez; Eduardo Ponce-España; Juan Carlos López; Nuria Álvarez-Sánchez; Ana Isabel Álvarez-López; Justo Pedroche; Francisco Millán; María Carmen Millán-Linares; Patricia Judith Lardone; Ignacio Bejarano; Ivan Cruz-Chamorro; Antonio Carrillo-Vico Journal: Int J Mol Sci Date: 2022-08-29 Impact factor: 6.208
Authors: Shu-Wei Liu; Chia-Yi Wu; Ming-Been Lee; Ming-Chi Huang; Chia-Ta Chan; Chun-Ying Chen Journal: Int J Environ Res Public Health Date: 2021-12-08 Impact factor: 3.390